iPSC– tag –
-
Novo Nordisk Confirms 12-Month Safety and Feasibility of ESC-Derived Dopaminergic Cell Therapy for Parkinson’s in Phase 1/2 Trial
Regen Report USA Overview Novo Nordisk has announced positive 12-month safety and feasibility data from its Phase 1/2 clinical trial of embryonic stem cell (ESC)-derived dopaminergic cells for Parkinson's disease, published in Nature Med... -
Global Pluripotent Stem Cell Therapies Progress to 115 Clinical Trials with Over 1,200 Patients, Demonstrating Strong Safety Profile
Vertex AI Search Global Overview Global clinical trials involving pluripotent stem cell therapies have significantly advanced, with 115 trials treating over 1,200 patients by December 2024, reporting no major safety concerns. This progre... -
Novel Stem Cell Approach Aims for Functional Cure in Diabetes, Pioneering Immunosuppression-Free Islet Cell Transplantation
News-Medical International Overview A new stem cell approach is targeting a functional cure for diabetes, specifically focusing on the potential for islet cell transplantation without immunosuppression, as reported on July 11, 2026. This... -
Wugen Rebrands as Allotera, Closes $35 Million Financing Round to Accelerate Off-the-Shelf Cell Therapy Development for Cancer and Autoimmune Diseases
Cellgenetherapyreview.com USA Overview On July 10, 2026, Wugen announced its rebranding to Allotera and the successful completion of a $35 million financing round. This rebranding and capital infusion represent a significant strategic st... -
Human Organoid Technology: A Review of Latest Developments and Applications Driving Disease Mechanism Discovery and Personalized Medicine
PubMed (Organoid journal) International Overview This review article, published on July 10, 2026, outlines the latest developments and applications of human organoid technology, highlighting its unique capacity for in vitro research into... -
Organoid Research Showcased at ISSCR 2026: iPSC and Adult Stem Cell-Derived Systems Drive Breakthroughs in Organogenesis and Disease Modeling
International Society for Stem Cell Research (ISSCR) International Overview The ISSCR 2026 annual meeting highlighted the latest innovations and technical advancements in organoid technology, particularly emphasizing iPSC and adult stem ... -
Sana Biotechnology Announces Groundbreaking 14-Month Durability Data for Hypoimmune-Modified Islet Cell Transplantation (UP421) in Type 1 Diabetes Without Immunosuppression, Published in The New England Journal of Medicine
GlobeNewswire (Sana Biotechnology) USA Overview Sana Biotechnology announced groundbreaking long-term durability data for its hypoimmune-modified islet cell transplant UP421 in Type 1 Diabetes patients, demonstrating 14 months of sustain... -
Space-Grown Organoids and Proteomics Synergize to Advance Human Disease Research for Complex Conditions like Retrosyndromes and Cancer
Scientific News Outlet USA Overview On July 17, 2026, the fusion of space-grown organoids and proteomics technology was reported to be significantly advancing research into complex human diseases such as retrosyndromes and cancer. Organo... -
Century Therapeutics Unveils Preclinical Data for iPSC-Derived Islet Replacement Therapy CNTY-813 for Type 1 Diabetes, Aiming for Immunosuppression-Free Treatment via Allo-Evasion™ 5.0 Technology and H2 2026 IND Filing
GlobeNewswire (Century Therapeutics) USA Overview Century Therapeutics announced that preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, will be presented at EASD 2026 and the Breakthrough T1D ... -
ISSCR to Host iPSC 20th Anniversary Symposium in Kyoto, Japan in October 2026, Celebrating Two Decades of Breakthrough Science
International Society for Stem Cell Research (ISSCR) Japan Overview The International Society for Stem Cell Research (ISSCR) announced a symposium in Kyoto, Japan, in October 2026, commemorating the 20th anniversary of iPSC discovery. Th...
